X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,110.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 25, 2024
Details:
CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pathological remodeling.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Inkef Capital
Deal Size: $76.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 25, 2021
Details:
The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
